Valuation: Inhalation Sciences Sweden AB

Market Cap 11.11M 1.15M 1.01M 929K 855K 1.61M 111M 1.64M 4.36M 54.11M 4.31M 4.21M 186M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 8.28M 855K 749K 692K 637K 1.2M 82.41M 1.22M 3.25M 40.32M 3.21M 3.14M 139M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2019-09-15
Chief Tech/Sci/R&D Officer - 2004-12-31
Corporate Officer/Principal - 2025-06-01
Director TitleAgeSince
Director/Board Member - 2004-12-31
Director/Board Member - 2022-08-31
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.21M
-1.17%-0.43%+29.95%-2.24% 198B
-1.33%+0.47%+6.93%-17.71% 144B
+2.24%-13.25%-31.57%+1.58% 122B
-0.59%-1.97%-57.82%-18.13% 65.44B
-0.85%-7.40%+11.02%-8.26% 49.36B
+0.65%+2.20%-23.34%-30.88% 44.74B
-0.91%-2.82%+16.26%+4.58% 37.13B
-3.10%-4.20%+26.94%+27.80% 36.23B
-0.19%+0.06%-23.92%-9.43% 28.7B
Average -0.50%-2.81%-5.06%-5.85% 80.68B
Weighted average by Cap. -0.44%-2.62%-0.45%-6.71%

Financials

2024 2025
Net sales 11.05M 1.14M 999K 924K 850K 1.6M 110M 1.63M 4.33M 53.8M 4.28M 4.19M 185M 3.04M 314K 275K 254K 234K 441K 30.27M 448K 1.19M 14.81M 1.18M 1.15M 51.03M
Net income -5.15M -531K -466K -430K -396K -747K -51.23M -759K -2.02M -25.07M -2M -1.95M -86.37M -10.16M -1.05M -919K -850K -781K -1.47M -101M -1.5M -3.98M -49.48M -3.94M -3.85M -170M
Net Debt -4M -413K -362K -335K -308K -581K -39.85M -590K -1.57M -19.5M -1.55M -1.52M -67.17M -2.83M -292K -256K -237K -218K -411K -28.18M -417K -1.11M -13.79M -1.1M -1.07M -47.5M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5